Last reviewed · How we verify
Vaccine FP-01.1
At a glance
| Generic name | Vaccine FP-01.1 |
|---|---|
| Sponsor | Immune Targeting Systems Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge (PHASE1, PHASE2)
- Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults (PHASE1)
- Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1) (PHASE1)
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaccine FP-01.1 CI brief — competitive landscape report
- Vaccine FP-01.1 updates RSS · CI watch RSS
- Immune Targeting Systems Ltd portfolio CI